DecisionDx®-Melanoma More Accurately Predicts the Risk of Your Melanoma Recurring or Spreading

As with all cancers, one of the primary challenges for healthcare professionals in managing melanoma is predicting the course of their patients’ disease. Having an accurate picture of whether the cancer is likely to recur or spread to a sentinel lymph node is critical to making the right treatment and management decisions.

Personalized Information From DecisionDx-Melanoma Can Improve the Treatment Plan Decisions You and Your Healthcare Professional Make

1

What’s the right monitoring plan for my melanoma?

For follow-up management plan decisions, knowing the risk of your cancer recurring is a critical part of developing an effective monitoring plan. Having additional personalized information from DecisionDx-Melanoma can help you and your healthcare professional make better decisions about treating and managing your melanoma.

2

Is sentinel lymph node biopsy right for me?

For many patients eligible for the sentinel lymph node biopsy (SLNB) surgical procedure, the DecisionDx-Melanoma test can provide important information to consider before deciding to have this procedure. 

DecisionDx-Melanoma Uses Tumor Biology to More Accurately Predict the Risk of Your Melanoma Recurring or Spreading

 
 
 

Addressing the need for a more accurate picture of individual risk, the DecisionDx-Melanoma test was developed to help predict the individual risk of recurrence based on the biology of a person’s tumor. The test can provide you and your healthcare professional with additional, independent information about your tumor’s biology that can be used to help plan your care.

If you have been diagnosed with melanoma, the DecisionDx-Melanoma test may be right for you. The test uses a small sample of the melanoma tissue, (generally taken from your original biopsy sample) to measure the activity of 31 specific genes found to be associated with progression of melanoma. Based on the tumor’s activity levels, DecisionDx-Melanoma classifies the tumor as lowest risk (Class 1A),  increased risk (Class 1B/2A), or highest risk (Class 2B).

skinmel-classeschart.svg
MySkinMel-testgraphic.jpg

Genomic Testing Adoption by Healthcare Professionals

 
 
 

Since its availability in 2015, over 68,900 patients have been clinically tested. Over 7,700 healthcare professionals ordered the DecisionDx-Melanoma test to guide their decisions on both the SLNB surgical procedure and post-surgical management plans. In fact, studies found that about one in two patients will have their management plans changed to one more appropriate for their specific situation when the DecisionDx-Melanoma test is incorporated into their care.

0+

patients tested since 2015
More than

0

Healthcare professionals have ordered the test
Approximately

0%

of patients have their clinical management plan changed after the DecisionDx-Melanoma test

What’s Next?

How Do You Get a
DecisionDx-Melanoma Test?

LEARN MORE

How Do You Use the Test Results?

LEARN MORE